Drugs / JSKN003
Trials 10 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05494918 | Sep 2022 → Apr 2025 | cancer, metastatic neoplasm | Alphamab (Australia) Co Pty Ltd. | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06226766 | Jan 2024 → Jul 2025 | neoplasm | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Terminated | No outcome recorded |
| Phase 1/2 | NCT05744427 | Mar 2023 → Jul 2026 overdue | neoplasm | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Active not recruiting | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT07545044 | May 2026 → May 2027 expected | HER2 positive breast carcinoma | Shanghai JMT-Bio Inc. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07283198 | Dec 2025 → Aug 2027 expected | non-small cell lung carcinoma | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06998771 | Jun 2025 → Jun 2028 expected | carcinoma | Shanghai JMT-Bio Inc. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05582499 | Nov 2022 → Dec 2027 expected | HER2 positive breast carcinoma, female breast carcinoma, hormone receptor-positive breast cancer, triple-negative breast carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT06846437 | Feb 2025 → Oct 2026 expected | HER2 positive breast carcinoma | Shanghai JMT-Bio Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT06751485 | Jan 2025 → Dec 2026 expected | fallopian tube cancer, ovarian carcinoma, primary peritoneal carcinoma | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06079983 | Dec 2023 → Apr 2026 overdue | breast cancer | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Recruiting | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07384377 Comparator | Feb 2026 → Nov 2027 expected | carcinoma | Shanghai JMT-Bio Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JSKN003 | “JSKN033 is a fixed-dose combination consisting of JSKN003 (a HER2-targeted ADC) and envafolimab (a PD-L1 inhibitor)” NCT07283198 ↗10“JSKN033 is a combination drug product comprised of JSKN003 and envafolimab for subcutaneous injection.” NCT06226766 ↗ |
| Modality | Monoclonal antibody | “an anti-HER2 ADC” NCT05582499 ↗ |
| Route | Intravenous | “administered via intravenous (IV) dose” NCT05494918 ↗ |
| Target | ERBB2 | “anti-Her2 ADC JSKN003” NCT05494918 ↗ |